Reportlinker Adds Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market

News provided by

Reportlinker

14 Apr, 2011, 07:01 ET

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market

http://www.reportlinker.com/p0481588/Travel-Vaccines-Market-to-2017---Growth-in-International-Travel-and-Higher-Incidences-of-Infectious-Diseases-in-Emerging-Economies-to-Drive-the-Market.html

Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Travel Vaccines Market to 2017 – Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market", which provides insights into the global travel vaccines market and market forecasts until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which travel vaccines are often prescribed, which includes hepatitis A, hepatitis B, rabies, typhoid fever, yellow fever, Japanese encephalitis and meningococcal meningitis. In addition, the report also includes insights into the travel vaccines R&D pipeline.

Scope

The scope of this report includes -

- Data and analysis on the global travel vaccines market.

- Annualized market data for the travel vaccines market from 2002 to 2010, with forecasts to 2017 for top seven geographies which includes the US, the UK, France, Germany, Italy, Spain and Japan.

- Market data on the therapeutic landscape which covers hepatitis A, hepatitis B, rabies, typhoid fever, yellow fever, Japanese encephalitis and meningococcal meningitis, including market size, market share and cost of vaccination.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The competitive landscape of the global travel vaccine market, which includes companies such as Sanofi-Pasteur, GlaxoSmithKline, Merck, Novartis and Intercell.

- Key M&A activities and Licensing Agreements that took place from 2005 to 2011 in the global travel vaccines market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth.

- Devise a more tailored country strategy through the understanding of key drivers and barriers of the region's antibacterial market.

- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 8

2 Global Travel Vaccines Market to 2017– Introduction 10

2.1 GBI Research Report Guidance 11

3 Global Travel Vaccines Market to 2017 – Market Overview 12

3.1 Introduction 12

3.2 Revenue Forecasts for the Travel Vaccines Market 12

3.3 Drivers and Barriers for the Travel Vaccines Market 13

3.3.1 Drivers for the Travel Vaccines Market 13

3.3.2 Barriers for the Travel Vaccines Market 14

4 Global Travel Vaccines Market to 2017 – Geographical Landscape 15

4.1 Revenue Analysis by Geography 15

4.1.1 The US 17

4.1.2 Top Five Countries of Europe 20

4.1.3 Japan 23

4.1.4 Rest of the World 26

5 Global Travel Vaccines Market to 2017 – Therapeutic Landscape 29

5.1 Hepatitis A 29

5.1.1 Introduction 29

5.1.2 Revenue 30

5.1.3 Cost of Vaccination 31

5.1.4 Vaccination Coverage 32

5.1.5 Drivers and Barriers for the Hepatitis A Market 33

5.2 Hepatitis B 34

5.2.1 Introduction 34

5.2.2 Revenue 35

5.2.3 Cost of Vaccination 36

5.2.4 Vaccination Coverage 37

5.2.5 Drivers and Barriers for the Hepatitis B Market 38

5.3 Rabies 39

5.3.1 Introduction 39

5.3.2 Revenue 40

5.3.3 Cost of Vaccination 41

5.3.4 Vaccination Coverage 42

5.3.5 Drivers and Barriers for the Rabies Market 43

5.4 Typhoid Fever 44

5.4.1 Introduction 44

5.4.2 Revenue 45

5.4.3 Cost of Vaccination 46

5.4.4 Vaccination Coverage 47

5.4.5 Drivers and Barriers for the Typhoid Fever Market 48

5.5 Yellow Fever 49

5.5.1 Introduction 49

5.5.2 Revenue 50

5.5.3 Cost of Vaccination 51

5.5.4 Vaccination Coverage 52

5.5.5 Drivers and Barriers for the Yellow Fever Market 53

5.6 Japanese Encephalitis 54

5.6.1 Introduction 54

5.6.2 Revenue 55

5.6.3 Cost of Vaccination 56

5.6.4 Vaccination Coverage 57

5.6.5 Drivers and Barriers for the Japanese Encephalitis Market 58

5.7 Meningococcal Meningitis 59

5.7.1 Introduction 59

5.7.2 Revenue 60

5.7.3 Cost of Vaccination 61

5.7.4 Vaccination Coverage 62

5.7.5 Drivers and Barriers for the Meningococcal Meningitis Market 63

5.8 Enterotoxigenic Escherichia Coli (Traveler's Diarrhea) 64

5.8.1 Introduction 64

5.8.2 Drivers and Barriers for the Enterotoxigenic Escherichia Coli Market 65

6 Travel Vaccines Market – Product Pipeline Analysis 66

6.1 Introduction 66

6.1.1 Research and Development Pipeline – Hepatitis A Vaccines 68

6.1.2 Research and Development Pipeline – Hepatitis B Vaccines 69

6.1.3 Research and Development Pipeline – Rabies Vaccines 74

6.1.4 Research and Development Pipeline – Typhoid Fever Vaccines 76

6.1.5 Research and Development Pipeline – Yellow Fever Vaccines 78

6.1.6 Research and Development Pipeline – Japanese Encephalitis Vaccines 79

6.1.7 Research and Development Pipeline – Enterotoxigenic Escherichia Coli Vaccines 80

6.1.8 Research and Development Pipeline – Meningococcal Meningitis Vaccines 81

7 Travel Vaccines Market – Competitive Landscape 84

7.1 Market Share Analysis: Travel Vaccines Market 84

7.2 Competitive Profiling 85

7.2.1 Sanofi Pasteur 85

7.2.2 GlaxoSmithKline plc 87

7.2.3 Merck & Co., Inc 88

7.2.4 Novartis AG 90

7.2.5 Intercell AG 91

8 Travel Vaccines Market – M&A Landscape 92

8.1 M&A Landscape 92

8.1.1 M&A Deals by Year 92

8.1.2 M&A Deals by Geography 93

8.1.3 M&A Deals by Value 94

8.1.4 Major M&A Deals by Value 95

8.1.5 M&A Deals by Deal Type 96

8.1.6 M&A Deals by Deal Sub-Type 97

8.2 R&D Licensing Agreements 98

8.2.1 Deals by Year 98

8.2.2 Deals by Geography 99

8.2.3 Deals by Value ($) 100

8.3 Co-Developments 101

8.3.1 Co-Developments by Year 101

8.3.2 Co-developments by Geography 102

9 Travel Vaccines Market – Appendix 103

9.1 Market Definitions 103

9.2 Abbreviations 103

9.3 Research Methodology 103

9.3.1 Coverage 103

9.3.2 Secondary Research 104

9.3.3 Primary Research 104

9.3.4 Expert Panel Validation 104

9.4 Contact Us 105

9.5 Disclaimer 105

9.6 Sources 105

1.1 List of Tables

Table 1: Travel Vaccines Therapeutics Market, Global, Revenue ($m), 2002-2010 12

Table 2: Travel Vaccines Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 12

Table 3: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 15

Table 4: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 16

Table 5: Travel Vaccines Therapeutics Market, the US, Revenue ($m), 2002-2010 17

Table 6: Travel Vaccines Therapeutics Market, the US, Revenue Forecasts ($m), 2010-2017 17

Table 7: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2002-2010 18

Table 8: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2010-2017 18

Table 9: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers (million), 2002-2010 19

Table 10: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers Forecasts (million), 2010-2017 19

Table 11: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2002- 2010 20

Table 12: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010- 2017 20

Table 13: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2002-2010 21

Table 14: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2010-2017 21

Table 15: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers (million), 2002-2010 22

Table 16: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers Forecasts (million), 2010-2017 22

Table 17: Travel Vaccines Therapeutics Market, Japan, Revenue ($m), 2002- 2010 23

Table 18: Travel Vaccines Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017 23

Table 19: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2002-2010 24

Table 20: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2010-2017 24

Table 21: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers (million), 2002-2010 25

Table 22: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers Forecasts (million), 2010-2017 25

Table 23: Travel Vaccines Therapeutics Market, Rest of the World, Revenue ($m), 2002-2010 26

Table 24: Travel Vaccines Therapeutics Market, Rest of the World, Revenue Forecasts ($m), 2010-2017 26

Table 25: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2002-2010 27

Table 26: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2010-2017 27

Table 27: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers (million), 2002-2010 28

Table 28: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers Forecasts (million), 2010-2017 28

Table 29: Hepatitis A Therapeutics Market, Global, Revenue ($m), 2002-2010 30

Table 30: Hepatitis A Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 30

Table 31: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 31

Table 32: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 31

Table 33: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 32

Table 34: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 32

Table 35: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2002-2010 35

Table 36: Hepatitis B Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 35

Table 37: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 36

Table 38: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 36

Table 39: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 37

Table 40: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 37

Table 41: Rabies Therapeutics Market, Global, Revenue ($m), 2002-2010 40

Table 42: Rabies Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 40

Table 43: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 41

Table 44: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 41

Table 45: Rabies Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 42

Table 46: Rabies Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 42

Table 47: Typhoid Fever Therapeutics Market, Global, Revenue ($m), 2002-2010 45

Table 48: Typhoid Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 45

Table 49: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 46

Table 50: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 46

Table 51: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 47

Table 52: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 47

Table 53: Yellow Fever Therapeutics Market, Global, Revenue ($m), 2002-2010 50

Table 54: Yellow Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 50

Table 55: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 51

Table 56: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 51

Table 57: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 52

Table 58: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 52

Table 59: Japanese Encephalitis Therapeutics Market, Global, Revenue ($m), 2002-2010 55

Table 60: Japanese Encephalitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 55

Table 61: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 56

Table 62: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 56

Table 63: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 57

Table 64: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 57

Table 65: Meningococcal Meningitis Therapeutics Market, Global, Revenue ($m), 2002-2010 60

Table 66: Meningococcal Meningitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 60

Table 67: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2010 61

Table 68: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2010-2017 61

Table 69: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers (million), 2002-2010 62

Table 70: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2010-2017 62

Table 71: Travel Vaccines Therapeutics Market, Global Product Pipeline by Phase, 2011 66

Table 72: Travel Vaccines Therapeutics Market, Global Product Pipeline by Indication, 2011 67

Table 73: Hepatitis A Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 68

Table 74: Hepatitis A Therapeutics Market, Pipeline, Phase III Molecules, 2011 68

Table 75: Hepatitis B Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 69

Table 76: Hepatitis B Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 70

Table 77: Hepatitis B Therapeutics Market, Pipeline, Phase I Molecules, 2011 70

Table 78: Hepatitis B Therapeutics Market, Pipeline, Phase II Molecules, 2011 71

Table 79: Hepatitis B Therapeutics Market, Pipeline, Phase III Molecules, 2011 73

Table 80: Rabies Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 75

Table 81: Rabies Therapeutics Market, Pipeline, Phase I Molecules, 2011 75

Table 82: Rabies Therapeutics Market, Pipeline, Phase II Molecules, 2011 75

Table 83: Typhoid Fever Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 76

Table 84: Typhoid Fever Therapeutics Market, Pipeline, Phase I Molecules, 2011 76

Table 85: Typhoid Fever Therapeutics Market, Pipeline, Phase II Molecules, 2011 77

Table 86: Yellow Fever Therapeutics Market, Pipeline, Phase I Molecules, 2011 78

Table 87: Yellow Fever Therapeutics Market, Pipeline, Phase II Molecules, 2011 78

Table 88: Japanese Encephalitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 79

Table 89: Japanese Encephalitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 79

Table 90: Enterotoxigenic Escherichia Coli Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 80

Table 91: Enterotoxigenic Escherichia Coli Therapeutics Market, Pipeline, Phase I Molecules, 2011 80

Table 92: Meningococcal Meningitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 81

Table 93: Meningococcal Meningitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 82

Table 94: Meningococcal Meningitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 83

Table 95: Travel Vaccines Therapeutics Market, Global, Major M&A Deals by Value ($m), 2004-2011 95

Table 96: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Value ($m), 2004-2011 100

1.2 List of Figures

Figure 1: Travel Vaccines Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 12

Figure 2: Travel Vaccines Therapeutics Market, Market Drivers and Barriers, 2010-2017 13

Figure 3: Travel Vaccines Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 15

Figure 4: Travel Vaccines Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2017 17

Figure 5: Travel Vaccines Therapeutics Market, the US, Cost of Vaccination ($), 2002-2017 18

Figure 6: Travel Vaccines Therapeutics Market, the US, Vaccinated Travelers Forecasts (million), 2002-2017 19

Figure 7: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 20

Figure 8: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Cost of Vaccination ($), 2002-2017 21

Figure 9: Travel Vaccines Therapeutics Market, Top Five Countries of Europe, Vaccinated Travelers Forecasts (million), 2002-2017 22

Figure 10: Travel Vaccines Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2017 23

Figure 11: Travel Vaccines Therapeutics Market, Japan, Cost of Vaccination ($), 2002-2017 24

Figure 12: Travel Vaccines Therapeutics Market, Japan, Vaccinated Travelers Forecasts (million), 2002-2017 25

Figure 13: Travel Vaccines Therapeutics Market, Rest of the World, Revenue Forecasts, 2002-2017 26

Figure 14: Travel Vaccines Therapeutics Market, Rest of the World, Cost of Vaccination ($), 2002-2017 27

Figure 15: Travel Vaccines Therapeutics Market, Rest of the World, Vaccinated Travelers Forecasts (million), 2002-2017 28

Figure 16: Hepatitis A Therapeutics Market, Geographical Distribution of Hepatitis A 29

Figure 17: Hepatitis A Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 30

Figure 18: Hepatitis A Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 31

Figure 19: Hepatitis A Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 32

Figure 20: Hepatitis A Therapeutics Market, Market Drivers and Barriers, 2010-2017 33

Figure 21: Hepatitis B Therapeutics Market, Geographical Distribution of Hepatitis B 34

Figure 22: Hepatitis B Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 35

Figure 23: Hepatitis B Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 36

Figure 24: Hepatitis B Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 37

Figure 25: Hepatitis B Therapeutics Market, Market Drivers and Barriers, 2010-2017 38

Figure 26: Rabies Vaccine Therapeutics Market, Geographical Distribution of Rabies 39

Figure 27: Rabies Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 40

Figure 28: Rabies Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 41

Figure 29: Rabies Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 42

Figure 30: Rabies Therapeutics Market, Market Drivers and Barriers, 2010-2017 43

Figure 31: Typhoid Fever Therapeutics Market, Geographical Distribution of Typhoid Fever 44

Figure 32: Typhoid Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 45

Figure 33: Typhoid Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 46

Figure 34: Typhoid Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 47

Figure 35: Typhoid Fever Therapeutics Market, Market Drivers and Barriers, 2010-2017 48

Figure 36: Yellow Fever Vaccine Therapeutics Market, Geographical Distribution of Yellow Fever 49

Figure 37: Yellow Fever Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 50

Figure 38: Yellow Fever Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 51

Figure 39: Yellow Fever Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 52

Figure 40: Yellow Fever Therapeutics Market, Market Drivers and Barriers, 2010-2017 53

Figure 41: Japanese Encephalitis Therapeutics Market, Geographical Distribution of Japanese Encephalitis 54

Figure 42: Japanese Encephalitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 55

Figure 43: Japanese Encephalitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 56

Figure 44: Japanese Encephalitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 57

Figure 45: Japanese Encephalitis Therapeutics Market, Market Drivers and Barriers, 2010-2017 58

Figure 46: Meningococcal Meningitis Therapeutics Market, Geographical Distribution of Meningococcal Meningitis 59

Figure 47: Meningococcal Meningitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 60

Figure 48: Meningococcal Meningitis Therapeutics Market, Global, Cost of Vaccination ($), 2002-2017 61

Figure 49: Meningococcal Meningitis Therapeutics Market, Global, Vaccinated Travelers Forecasts (million), 2002-2017 62

Figure 50: Meningococcal Meningitis Therapeutics Market, Market Drivers and Barriers, 2010-2017 63

Figure 51: Travel Vaccine Therapeutics Market, Global, Geographical Distribution of Enterotoxigenic Escherischia Coli 64

Figure 52: Enterotoxigenic Escherischia Coli Therapeutics Market, Market Drivers and Barriers, 2010-2017 65

Figure 53: Travel Vaccines Therapeutics Market, Global Product Pipeline by Phase (%), 2011 66

Figure 54: Travel Vaccines Therapeutics Market, Global Product Pipeline by Indication (%), 2011 67

Figure 55: Hepatitis A Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 68

Figure 56: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 69

Figure 57: Rabies Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 74

Figure 58: Typhoid Fever Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 76

Figure 59: Yellow Fever Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 78

Figure 60: Japanese Encephalitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 79

Figure 61: Enterotoxigenic Escherichia Coli Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 80

Figure 62: Meningococcal Meningitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 81

Figure 63: Travel Vaccines Therapeutics Market, Global, Market Share Analysis by Company (%), 2010 84

Figure 64: Travel Vaccines Therapeutics Market, Sanofi Pasteur, Company Overview, 2011 85

Figure 65: Travel Vaccines Therapeutics Market, Sanofi Pasteur, SWOT Analysis, 2011 86

Figure 66: Travel Vaccines Therapeutics Market, GSK, Company Overview, 2011 87

Figure 67: Travel Vaccines Therapeutics Market, GSK, SWOT Analysis, 2011 88

Figure 68: Travel Vaccines Therapeutics Market, Merck & Co., Inc, Company Overview, 2011 88

Figure 69: Travel Vaccines Therapeutics Market, Merck & Co., SWOT Analysis, 2011 89

Figure 70: Travel Vaccines Therapeutics Market, Novartis AG, Company Overview, 2011 90

Figure 71: Travel Vaccines Therapeutics Market, Novartis AG, SWOT Analysis, 2011 90

Figure 72: Travel Vaccines Therapeutics Market, Intercell AG, Company Overview, 2011 91

Figure 73: Travel Vaccines Therapeutics Market, Intercell AG, SWOT Analysis, 2011 91

Figure 74: Travel Vaccines Therapeutics Market, Global, M&A Deals by Year, 2004-2011 92

Figure 75: Travel Vaccines Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 93

Figure 76: Travel Vaccines Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011 94

Figure 77: Travel Vaccines Therapeutics Market, Global, M&A Deals by Deal Type, 2004-2011 96

Figure 78: Travel Vaccines Therapeutics Market, Global, M&A Deals by Deal Sub-Type, 2004-2011 97

Figure 79: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011 98

Figure 80: Travel Vaccines Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011 99

Figure 81: Travel Vaccines Therapeutics Market, Global, Co-Developments by Year (%), 2004-2011 101

Figure 82: Travel Vaccines Therapeutics Market, Global, Co-Developments by Geography (%), 2004-2011 102

Companies mentioned

Sanofi Pasteur

GlaxoSmithKline plc

Merck & Co., Inc

Novartis AG

Intercell AG

To order this report:

: Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.